NO20083821L - Polymerpreparater av CETP-inhibitorer - Google Patents
Polymerpreparater av CETP-inhibitorerInfo
- Publication number
- NO20083821L NO20083821L NO20083821A NO20083821A NO20083821L NO 20083821 L NO20083821 L NO 20083821L NO 20083821 A NO20083821 A NO 20083821A NO 20083821 A NO20083821 A NO 20083821A NO 20083821 L NO20083821 L NO 20083821L
- Authority
- NO
- Norway
- Prior art keywords
- cetp inhibitors
- polymer preparations
- cholesterol levels
- compound
- cetp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Farmasøytisk preparat omfattende (a) en CETP-inhiberende forbindelse eller et farmasøytisk akseptabelt salt av denne, (b) en konsentrasjonsforbedrende polymer, og (c) eventuelt ett eller flere overflateaktive stoffer, hvor forbindelsen har strukturen vist ved formel I nedenfor. Preparatet øker HDL-kolesterolnivået og senker LDL-kolesterolnivået.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77178206P | 2006-02-09 | 2006-02-09 | |
PCT/US2007/003799 WO2007092642A2 (en) | 2006-02-09 | 2007-02-09 | Polymer formulations of cetp inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20083821L true NO20083821L (no) | 2008-09-30 |
NO341326B1 NO341326B1 (no) | 2017-10-16 |
Family
ID=38198472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083821A NO341326B1 (no) | 2006-02-09 | 2008-09-08 | Farmasøytisk sammensetning av CETP-inhibitorer, deres anvendelse ved terapi, og for å øke HDL-kolesterol, samt deres anvendelse ved fremstilling av et medikament for å øke HDL-kolesterolet. |
Country Status (14)
Country | Link |
---|---|
US (1) | US8030359B2 (no) |
EP (1) | EP1983966B1 (no) |
JP (2) | JP5773560B2 (no) |
KR (1) | KR101418267B1 (no) |
CN (2) | CN103735515A (no) |
AU (1) | AU2007212197B2 (no) |
BR (1) | BRPI0707584A2 (no) |
CA (1) | CA2641451C (no) |
IL (1) | IL192977A (no) |
NO (1) | NO341326B1 (no) |
NZ (1) | NZ569700A (no) |
RU (1) | RU2457841C2 (no) |
WO (1) | WO2007092642A2 (no) |
ZA (1) | ZA200805854B (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004085996A2 (en) | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CN103102303B (zh) * | 2004-12-31 | 2015-10-28 | 雷迪博士实验室有限公司 | 作为cetp抑制剂的苄胺衍生物 |
MX2010004292A (es) * | 2007-10-19 | 2010-08-02 | Abbott Gmbh & Co Kg | Producto de dispersion solida que contiene un compuesto a base de n-aril urea. |
WO2009108720A2 (en) | 2008-02-25 | 2009-09-03 | Amira Pharmaceuticals, Inc. | Antagonists of prostaglandin d2 receptors |
AR071375A1 (es) * | 2008-04-22 | 2010-06-16 | Solvay Pharm Gmbh | Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto |
ES2836809T3 (es) | 2010-11-24 | 2021-06-28 | Melinta Subsidiary Corp | Composiciones farmacéuticas |
ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
KR101774223B1 (ko) | 2011-08-18 | 2017-09-12 | 닥터 레디스 레보러터리즈 리미티드 | 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물 |
JP6140168B2 (ja) | 2011-09-27 | 2017-05-31 | ドクター レディズ ラボラトリーズ リミテッド | アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体 |
EP2854816B1 (en) * | 2012-05-31 | 2020-07-08 | Merck Sharp & Dohme Corp. | Solid dosage formulations of an orexin receptor antagonist |
PT2874607T (pt) * | 2012-07-17 | 2017-08-14 | Dow Global Technologies Llc | Resumo |
JP6301339B2 (ja) * | 2012-09-27 | 2018-03-28 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 少なくとも1種の水溶性ビタミンe誘導体および少なくとも1種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤 |
CN104918608A (zh) | 2012-11-19 | 2015-09-16 | 雷迪博士实验室有限公司 | Cetp抑制剂的药物组合物 |
KR102601617B1 (ko) * | 2013-11-22 | 2023-11-10 | 머크 샤프 앤드 돔 엘엘씨 | 비-뉴클레오시드 역전사 효소 억제제의 조성물 |
WO2015119848A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
CN106999491A (zh) * | 2014-11-28 | 2017-08-01 | 兴和株式会社 | 医药 |
JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
CN111803632B (zh) * | 2019-04-09 | 2022-04-29 | 北京五和博澳药业股份有限公司 | 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途 |
TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US6627767B2 (en) | 2000-08-29 | 2003-09-30 | Abbott Laboratories | Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors |
ATE361758T1 (de) | 2001-06-22 | 2007-06-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
ATE510817T1 (de) | 2002-01-29 | 2011-06-15 | Merck Serono Sa | Substituierte methylenamidderivate als modulatoren von proteintyrosinphosphatasen (ptps) |
DE60322665D1 (de) * | 2002-02-01 | 2008-09-18 | Pfizer Prod Inc | Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors |
WO2003063821A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
PT1533292E (pt) * | 2002-08-30 | 2007-05-31 | Japan Tobacco Inc | Compostos de dibenzilamina e sua utilização farmacêutica. |
KR100857759B1 (ko) | 2003-03-17 | 2008-09-09 | 니뽄 다바코 산교 가부시키가이샤 | Cetp 억제제의 약제학적 조성물 |
JPWO2004092136A1 (ja) | 2003-04-18 | 2006-07-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
CN102757397A (zh) * | 2005-07-01 | 2012-10-31 | 默沙东公司 | 合成cetp抑制剂的方法 |
ATE516016T1 (de) * | 2005-12-05 | 2011-07-15 | Merck Sharp & Dohme | Selbstemulgierende formulierungen von cetp- hemmern |
-
2007
- 2007-02-09 CA CA2641451A patent/CA2641451C/en not_active Expired - Fee Related
- 2007-02-09 AU AU2007212197A patent/AU2007212197B2/en not_active Ceased
- 2007-02-09 BR BRPI0707584-7A patent/BRPI0707584A2/pt not_active Application Discontinuation
- 2007-02-09 US US12/223,272 patent/US8030359B2/en not_active Expired - Fee Related
- 2007-02-09 CN CN201410027847.9A patent/CN103735515A/zh active Pending
- 2007-02-09 NZ NZ569700A patent/NZ569700A/en not_active IP Right Cessation
- 2007-02-09 WO PCT/US2007/003799 patent/WO2007092642A2/en active Application Filing
- 2007-02-09 EP EP07763707.2A patent/EP1983966B1/en not_active Not-in-force
- 2007-02-09 CN CN200780004561.7A patent/CN101378731B/zh not_active Expired - Fee Related
- 2007-02-09 JP JP2008554428A patent/JP5773560B2/ja not_active Expired - Fee Related
- 2007-02-09 RU RU2008136198/15A patent/RU2457841C2/ru not_active IP Right Cessation
- 2007-02-09 KR KR1020087019569A patent/KR101418267B1/ko active IP Right Grant
-
2008
- 2008-07-04 ZA ZA200805854A patent/ZA200805854B/xx unknown
- 2008-07-22 IL IL192977A patent/IL192977A/en not_active IP Right Cessation
- 2008-09-08 NO NO20083821A patent/NO341326B1/no not_active IP Right Cessation
-
2012
- 2012-11-22 JP JP2012255810A patent/JP5648038B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5773560B2 (ja) | 2015-09-02 |
CN103735515A (zh) | 2014-04-23 |
WO2007092642A2 (en) | 2007-08-16 |
JP5648038B2 (ja) | 2015-01-07 |
KR101418267B1 (ko) | 2014-07-11 |
IL192977A0 (en) | 2009-02-11 |
EP1983966A2 (en) | 2008-10-29 |
RU2008136198A (ru) | 2010-03-20 |
NO341326B1 (no) | 2017-10-16 |
JP2013067635A (ja) | 2013-04-18 |
US8030359B2 (en) | 2011-10-04 |
CA2641451C (en) | 2012-10-02 |
WO2007092642A3 (en) | 2007-10-04 |
AU2007212197A1 (en) | 2007-08-16 |
RU2457841C2 (ru) | 2012-08-10 |
CN101378731A (zh) | 2009-03-04 |
ZA200805854B (en) | 2009-10-28 |
EP1983966B1 (en) | 2013-06-26 |
BRPI0707584A2 (pt) | 2011-05-10 |
CN101378731B (zh) | 2014-03-05 |
US20100227903A1 (en) | 2010-09-09 |
KR20080108420A (ko) | 2008-12-15 |
NZ569700A (en) | 2011-09-30 |
JP2009526075A (ja) | 2009-07-16 |
AU2007212197B2 (en) | 2012-12-13 |
IL192977A (en) | 2011-01-31 |
CA2641451A1 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083821L (no) | Polymerpreparater av CETP-inhibitorer | |
WO2008131000A3 (en) | 7-substituted indole mcl-1 inhibitors | |
WO2015017813A3 (en) | Inhibitors of the farnesoid x receptor and uses in medicine | |
WO2009152356A3 (en) | Compounds and compositions useful for the treatment of malaria | |
NO20090469L (no) | Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
MY174452A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
WO2010068760A3 (en) | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | |
EA201500871A1 (ru) | Ингибиторы репликации вирусов гриппа | |
CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
WO2007107470A3 (en) | Pyrazoles as 11-beta-hsd-1 | |
WO2007027532A3 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
WO2009144555A8 (en) | Pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
NO20091845L (no) | Macrocykliske peptider som hepatitt C virus-inhibitorer | |
EA201170772A1 (ru) | Органические соединения | |
WO2012054110A3 (en) | Compounds and methods for inhibiting phosphate transport | |
MX2007012212A (es) | 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa. | |
WO2007032028A8 (en) | Thiazolinones and oxazolinones and their use as ptp1b inhibitors | |
WO2008013987A3 (en) | N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones | |
AR063550A2 (es) | Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad | |
WO2007034279A3 (en) | C3a antagonists and pharmaceutical compositions thereof | |
IN2015DN02966A (no) | ||
WO2013040227A3 (en) | Therapeutic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |